PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16125045

Magnesium sulfate: the first-line tocolytic.

David F Lewis
View original source ↗Export metadata ↓

Abstract

Magnesium sulfate has become the first-line tocolytic for short-term use to arrest idiopathic preterm labor. The reasons for its acceptance include familiarity of the drug, ease of use, and the virtual absence of serious maternal side effects. Sufficient data exist showing its efficacy if used in higher doses. Attention to treating preterm labor has shifted to seeking answers about the fundamental causes. Gathering information about the specific causes and designing tailor-made treatment protocols for each of the numerous potential causes is essential. Scientifically sound research is needed to obtain answers about the important clinical questions surrounding magnesium sulfate.

Explore related subjects

Drug Therapy, CombinationFemaleHumansMagnesium SulfateObstetric Labor, PrematurePregnancyTocolytic AgentsTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

David F Lewis. 2005. Magnesium sulfate: the first-line tocolytic.. https://doi.org/10.1016/j.ogc.2005.03.002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗